Joachim B Kohn

US Patent:

6337198, Jan 8, 2002

Filed:

Jun 27, 2000

Appl. No.:

09/604945

Inventors:

Howard B. Levene - Piscataway NJ
Christelle M. Lhommeau - Highland Park NJ
Joachim B Kohn - Highland Park NJ

Assignee:

Rutgers, The State University - New Brunswick NJ

International Classification:

C21N 1100

US Classification:

435174, 435177, 435180, 435182, 521 841

Abstract:

Biodegradable and biocompatible porous scaffolds characterized by a substantially continuous polymer phase, having a highly interconnected bimodal distribution of open pore sizes with rounded large pores of about 50 to about 500 microns in diameter and rounded small pores less than 20 microns in diameter, wherein the small pores are aligned in an orderly linear fashion within the walls of the large pores. Methods of preparing polymeric tissue scaffolds are also disclosed.

US Patent:

6359102, Mar 19, 2002

Filed:

Jun 29, 1998

Appl. No.:

09/107753

Inventors:

John E. Kemnitzer - Plainsboro NJ
George L. Brode - Bridgewater NJ
Joachim B. Kohn - Highland Park NJ

Assignee:

Integra LifeSciences I, Ltd. - Plainsboro NJ

International Classification:

C08G 6424

US Classification:

528179, 525183, 525184, 525196, 525199, 525210, 525288, 525332, 525368, 525371, 525422

Abstract:

Improvements are disclosed for biphasic polymerization processes in which an aqueous solution of a first monomer that is hydrolytically unstable below a pH of about six or above a pH of about eight is admixed with a water-immiscible organic solvent and there is added to the admixture a catalyst selected from tertiary amine, quaternary amine and phosphonium catalysts, an acid-forming co-monomer for the first monomer, an acid scavenger, after which the resulting polymer is recovered, wherein the improvement includes providing the aqueous solution at a pH between about si and about eight, and adding to the admixture the acid-forming co-monomer and the acid scavenger at relative rates effective to maintain the pH of the admixture between about six and about eight. The catalyst may be added in a molar ratio to the first monomer effective to provide a predetermined weight-average or number-average molecular weight for the resulting polymer. Biphasic polymerization processes for monomers that are not pH sensitive are also disclosed.

US Patent:

RE37795, Jul 16, 2002

Filed:

Jul 21, 1999

Appl. No.:

09/358015

Inventors:

Joachim B. Kohn - Highland Park NJ 08904
Stephen Brocchini - London, WC1N 1AX, GB
Arthur L. Schwartz - East Windsor NJ 08520

International Classification:

C08G 6800

US Classification:

528176, 560 38, 560 39, 560 40

Abstract:

A method for preparing diphenol compounds, which method includes the steps of coupling a hydroxyphenyl carboxylic acid with a L-tyrosine ester in a water-miscible organic reaction solvent containing a carbodiimide capable of forming a water-soluble urea by-product, thereby forming a diphenol reaction product; and combining the reaction mixture with an amount of water effective to precipitate the diphenol as a water-immiscible organic phase, so that a water-immiscible organic phase is formed containing the diphenol reaction product. New diphenol monomers and polymers polymerized therefrom are also discussed.

US Patent:

6475477, Nov 5, 2002

Filed:

Jul 3, 2000

Appl. No.:

09/554027

Inventors:

Joachim B. Kohn - Highland Park NJ
Durgadas Bolikal - Edison NJ
Sanyog M. Pendharkar - Old Bridge NJ

Assignee:

Rutgers, The State University - New Brunswick NJ

International Classification:

A61K 3174

US Classification:

424 7808, 424 7801, 424 7802, 424 7817, 424 111, 424 165, 424 91, 528176, 528182, 528206, 525432

Abstract:

Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic dihydroxy monomers can be employed as radio-opacifying, biocompatible non-toxic additives for other polymeric biomaterials. Radio-opaque medical implants and drug delivery devices for implantation prepared from the polymers of the present invention are also disclosed.

US Patent:

6517824, Feb 11, 2003

Filed:

May 20, 1996

Appl. No.:

08/650324

Inventors:

Joachim Kohn - Highland Park NJ
George J. Poiani - Jamesburg NJ
David J. Riley - New Brunswick NJ

Assignee:

University of Medicine Denistry of New Jersey - New Brunswick NJ
Rutgers University - New Brunswick NJ

International Classification:

A61K 3174

US Classification:

424 7806, 424 7817, 424 7808, 424 7827

Abstract:

A method for treating pulmonary hypertension and other diseases involving a defect in collagen metabolism, by administration of an effective amount of a liposome encapsulated copolymer conjugate antifibrotic composition, is disclosed. The antifibrotic agent is preferably a proline analog, such as cis-4-hydroxy-L-proline (cHyp). Consistent, high loadings ( 98%) of the antifibrotic agent are achieved by first forming a dipeptide with L-lysine, after which the dipeptide is copolymerized with the polymer component to form the copolymer conjugate. The polymer is preferably poly(ethylene glycol) having a weight average molecular weight of from about 500 to about 15,000. There is thus provided the efficient delivery and rateable release of the antifibrotic agent to inhibit collagen accumulation and thereby treat the diseases involved. Accordingly, there is a substantial reduction in the quantity of antifibrotic agent necessary, and thus a corresponding reduction in the potential for toxicity that would otherwise result from its prolonged administration.

US Patent:

6602497, Aug 5, 2003

Filed:

Jun 26, 2000

Appl. No.:

09/554021

Inventors:

Joachim B. Kohn - Highland Park NJ
Durgadas Bolikal - Edison NJ
Francesca DAcunzo - Piscataway NJ

Assignee:

Rutgers, The State University - New Brunswick NJ

International Classification:

A61K 3174

US Classification:

424 7808, 424 7817, 521 30

Abstract:

A polyether copolymer characterized by strictly alternating poly(alkyleneoxide) and aromatic diol monomeric repeating units, wherein the combination of repeating units is effective to provide said polyether with a hydrophillic/hydrophobic ratio at which aqueous micelle self-assembly occurs.

US Patent:

6852308, Feb 8, 2005

Filed:

Nov 5, 2002

Appl. No.:

10/288076

Inventors:

Joachim B. Kohn - Highland Park NJ, US
Durgadas Bolikal - Edison NJ, US
Sanyog M. Pendharkar - Old Bridge NJ, US

Assignee:

Rutgers, The State University - New Brunswick NJ

International Classification:

A61B010/00

US Classification:

424 96, 424 7808, 424 7801, 424 111, 424 165, 528176

Abstract:

Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic dihydroxy monomers can be employed as radio-opacifying, biocompatible non-toxic additives for other polymeric biomaterials. Radio-opaque medical implants and drug delivery devices for implantation prepared from the polymers of the present invention are also disclosed.

US Patent:

7005454, Feb 28, 2006

Filed:

Feb 24, 1999

Appl. No.:

09/257145

Inventors:

Stephen Brocchini - Highland Park NJ, US
Stephen R. Hanson - Stone Mountain GA, US
Joachim B. Kohn - Highland Park NJ, US

Assignee:

Rutgers, The State University - New Brunswick NJ

International Classification:

A61K 47/30
A61K 47/32
A61K 47/34

US Classification:

5147721, 514772, 5147723, 424486

Abstract:

Polymeric drug formulations containing a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix. Polymeric drug formulations are also disclosed containing a single-phase dispersion of a water-soluble drug and a water-insoluble tissue-compatible polymer matrix, and a second, phase-disrupting polymer that is non-miscible with the tissue-compatible polymer and is present in an amount sufficient to form phase-separated microdomains of the second polymer in the tissue-compatible polymer matrix, so that the release rate of the water-soluble drug from the tissue-compatible polymer matrix is related to the amount of the second polymer. Methods of preparing the polymeric drug formulations are also described, as well as methods for site-specific drug delivery utilizing the polymeric drug formulations.